
Anika Therapeutics Inc.: updates and filings
Price
$13.19
November 20, 2026Market cap $177M
What Ploutos Investor adds for Anika Therapeutics
Part of Ploutos Investor, €9.99 a month
- The full history: 17 fiscal years, from 2009
- The estimated fair value, with its range and its certainty
- The full analysis, 18 a month
- More questions to the chat on its filings
- Excel with every year
- An email when it reports, changes its dividend or an officer buys
Sign in with a free account to see the last 5 fiscal years.
What comes next, and what happened
Its next results and latest dividend, and the filings that told of something: results, deals, people, debt. In plain words, each linked to the filing.
Next results
last Nov 6, 2026next Jan 29, 2027
An estimate from when it has reported before, which has been regular. The company announces the date itself.
November 2026
July 2026
April 2026
Its SEC filings
What it has filed lately, newest first, linked to the document itself.
- Nov 6, 2026Quarterly reportfor the period to Sep 30, 2026Form10-Q
- Nov 6, 2026Results of operationsForm8-K
- Jul 31, 2026Over-5% holder statement (passive) (amendment)FormSCHEDULE 13G/A
- Jul 29, 2026Shares registered for employeesFormS-8
- Jul 29, 2026Quarterly reportfor the period to Jun 30, 2026Form10-Q
- Jul 29, 2026Results of operationsForm8-K
- Jul 17, 2026Over-5% holder statement (passive) (amendment)FormSCHEDULE 13G/A
- Jul 14, 2026Material agreement entered, new material financial obligationForm8-K
- Jun 23, 2026Officer or director change, shareholder voteForm8-K
- Jun 8, 2026Additional annual meeting materialFormDEFA14A
- Jun 1, 2026Additional annual meeting materialFormDEFA14A
- Apr 30, 2026Quarterly reportfor the period to Mar 31, 2026Form10-Q
- Apr 29, 2026Over-5% holder statement (passive)FormSCHEDULE 13G
- Apr 29, 2026Results of operations, officer or director changeForm8-K
- Apr 28, 2026Annual report to shareholdersfor the period to Dec 31, 2025FormARS
- Apr 28, 2026Additional annual meeting materialFormDEFA14A
- Apr 28, 2026Annual meeting proxy statementFormDEF 14A
- Mar 26, 2026Over-5% holder statement (passive) (amendment)FormSCHEDULE 13G/A
- Mar 3, 2026Annual reportfor the period to Dec 31, 2025Form10-K
- Feb 26, 2026Results of operations, officer or director changeForm8-K
- Jan 27, 2026Over-5% holder statement (active) (amendment)FormSCHEDULE 13D/A
- Jan 8, 2026Results of operations, officer or director changeForm8-K
- Jan 8, 2026Over-5% holder statement (passive) (amendment)FormSCHEDULE 13G/A
- Nov 21, 2025Over-5% holder statement (active) (amendment)FormSCHEDULE 13D/A
- Nov 7, 2025Over-5% holder statement (passive) (amendment)FormSCHEDULE 13G/A
| Filed | Form | What it is | Filing |
|---|---|---|---|
| Nov 6, 2026 | 10-Q | Quarterly reportfor the period to Sep 30, 2026 | Document |
| Nov 6, 2026 | 8-K | Results of operations | Document |
| Jul 31, 2026 | SCHEDULE 13G/A | Over-5% holder statement (passive) (amendment) | Document |
| Jul 29, 2026 | S-8 | Shares registered for employees | Document |
| Jul 29, 2026 | 10-Q | Quarterly reportfor the period to Jun 30, 2026 | Document |
| Jul 29, 2026 | 8-K | Results of operations | Document |
| Jul 17, 2026 | SCHEDULE 13G/A | Over-5% holder statement (passive) (amendment) | Document |
| Jul 14, 2026 | 8-K | Material agreement entered, new material financial obligation | Document |
| Jun 23, 2026 | 8-K | Officer or director change, shareholder vote | Document |
| Jun 8, 2026 | DEFA14A | Additional annual meeting material | Document |
| Jun 1, 2026 | DEFA14A | Additional annual meeting material | Document |
| Apr 30, 2026 | 10-Q | Quarterly reportfor the period to Mar 31, 2026 | Document |
| Apr 29, 2026 | SCHEDULE 13G | Over-5% holder statement (passive) | Document |
| Apr 29, 2026 | 8-K | Results of operations, officer or director change | Document |
| Apr 28, 2026 | ARS | Annual report to shareholdersfor the period to Dec 31, 2025 | Document |
| Apr 28, 2026 | DEFA14A | Additional annual meeting material | Document |
| Apr 28, 2026 | DEF 14A | Annual meeting proxy statement | Document |
| Mar 26, 2026 | SCHEDULE 13G/A | Over-5% holder statement (passive) (amendment) | Document |
| Mar 3, 2026 | 10-K | Annual reportfor the period to Dec 31, 2025 | Document |
| Feb 26, 2026 | 8-K | Results of operations, officer or director change | Document |
| Jan 27, 2026 | SCHEDULE 13D/A | Over-5% holder statement (active) (amendment) | Document |
| Jan 8, 2026 | 8-K | Results of operations, officer or director change | Document |
| Jan 8, 2026 | SCHEDULE 13G/A | Over-5% holder statement (passive) (amendment) | Document |
| Nov 21, 2025 | SCHEDULE 13D/A | Over-5% holder statement (active) (amendment) | Document |
| Nov 7, 2025 | SCHEDULE 13G/A | Over-5% holder statement (passive) (amendment) | Document |
From the company's record at the SEC (EDGAR). The topics of each 8-K are the item codes the company itself filed. Its whole record at the SEC, since Feb 22, 1996.
The full analysis
What do Anika Therapeutics's filings show?
The filings are where every one of Anika Therapeutics's figures comes from. The full Ploutos AI analysis reads everything the company has filed and shows what stands behind it, with a source for every figure.
- A fair value range built from the filings
- Earnings quality, debt and red flags
- Insider and institutional moves
- The case for and the case against
Related pages
The other pages on US stocks, free to read. On the company pages, the last three fiscal years are open to everyone, five with a free account, and every year with Ploutos Investor.
The figures come from the company's SEC filings and the share price, and describe what it has reported. They are not a score or a fair value.